Includes dose adjustments, warnings and precautions. Dose & infusion calculator panzyga® 10% (human normal immunoglobulin) solution for intravenous infusion Solution for infusion containing 100 mg/ml protein of which >95% is human normal igg Iga content < 0.3 mg/ml.1 panzyga® is indicated for replacement therapy in patients with primary and secondary immunode ciencies and as immunomodulation therapy in speci c autoimmune and neurological. Thrombosis may occur with immune globulin intravenous (igiv) products, including panzyga Advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.
Panzyga prescription and dosage information for physicians and health care professionals Pharmacology, adverse reactions, warnings, and panzygaside effects. In the pi study, 50 pediatric and adult subjects underwent pharmacokinetic assessments Subjects received infusions of panzyga (200 to 800 mg/kg body weight) every 3 or 4 weeks for 12 months Blood samples for pk study were collected between the 7 th and 9 th panzyga infusion, depending on the individual treatment schedule. Advanced age, prolonged immobilization, hypercoagulable conditions, history of.
These well considered features reinforce our commitment and support to tailoring optimised solutions for healthcare professionals, patients and caregivers. Panzyga package insert / prescribing information for healthcare professionals Indications, dosage, adverse reactions and pharmacology.
OPEN
